Last Updated: November 16, 2026

Vilazodone hydrochloride - Generic Drug Details

« Back to Dashboard


What are the generic drug sources for vilazodone hydrochloride and what is the scope of patent protection?

Vilazodone hydrochloride is the generic ingredient in two branded drugs marketed by Abbvie, Accord Hlthcare, Alembic, Apotex, Invagen Pharms, and Teva Pharms Usa, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

Thirteen suppliers are listed for this compound.

Recent Clinical Trials for vilazodone hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Global Coalition for Adaptive ResearchPHASE2
Idorsia Pharmaceuticals Ltd.PHASE2
Berry ConsultantsPHASE2

See all vilazodone hydrochloride clinical trials

Medical Subject Heading (MeSH) Categories for vilazodone hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for vilazodone hydrochloride
Paragraph IV (Patent) Challenges for VILAZODONE HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIIBRYD Tablets vilazodone hydrochloride 10 mg, 20 mg, and 40 mg 022567 5 2015-01-21

US Patents and Regulatory Information for vilazodone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Invagen Pharms VILAZODONE HYDROCHLORIDE vilazodone hydrochloride TABLET;ORAL 208200-001 Apr 7, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Alembic VILAZODONE HYDROCHLORIDE vilazodone hydrochloride TABLET;ORAL 208202-002 Jan 10, 2020 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms Usa VILAZODONE HYDROCHLORIDE vilazodone hydrochloride TABLET;ORAL 208212-002 Sep 30, 2019 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for vilazodone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 5,532,241 ⤷  Start Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 5,532,241 ⤷  Start Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 5,532,241 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Vilazodone Hydrochloride Market Dynamics, Generic Competition, Patents and Financial Trajectory

Last updated: November 5, 2026

Vilazodone hydrochloride, marketed in the United States as Viibryd, is an oral antidepressant approved for major depressive disorder in adults. Its commercial position has shifted from branded growth to generic erosion. The molecule benefited from a differentiated pharmacology and early market exclusivity, but it competes in a crowded antidepressant market where sertraline, escitalopram, fluoxetine, duloxetine and bupropion are available at low cost.

The commercial outlook is now driven by generic penetration, payer substitution and the remaining value of the Viibryd brand. Patent protection delayed full generic access, but the core composition-of-matter protection has a 2027 expiration date, subject to applicable patent-term adjustment and pediatric exclusivity. FDA approval of multiple generic vilazodone products has materially reduced long-term brand revenue potential.

What is vilazodone hydrochloride and how does it work?

Vilazodone hydrochloride is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist. The product is supplied as immediate-release tablets in 10 mg, 20 mg and 40 mg strengths. The FDA approved Viibryd in January 2011 for the treatment of major depressive disorder in adults. The recommended target dose is 20 mg or 40 mg once daily with food, after titration from a lower starting dose. [1]

Its dual pharmacology was positioned as a point of differentiation from conventional SSRIs. That differentiation did not create a durable pricing advantage because antidepressant prescribing is heavily influenced by generic substitution, formulary placement, tolerability, clinical familiarity and treatment cost.

Product attribute Vilazodone hydrochloride
Brand Viibryd
Active ingredient Vilazodone hydrochloride
Drug class SSRI and 5-HT1A partial agonist
Primary FDA indication Major depressive disorder in adults
Dosage form Immediate-release oral tablets
Strengths 10 mg, 20 mg, 40 mg
Original sponsor Forest Laboratories
Current branded commercial owner AbbVie, following the Allergan acquisition
FDA approval 2011
Generic status Multiple FDA-approved generic products
Principal commercial risk Generic substitution and low-cost SSRI competition

How large is the vilazodone hydrochloride market?

The market is best understood as a mature branded antidepressant franchise with declining exclusivity value rather than as a high-growth specialty pharmaceutical.

Viibryd initially generated growth through its newer mechanism, physician promotion and Forest Laboratories' established central nervous system commercial infrastructure. Forest later became part of Actavis, which became Allergan, and Allergan was acquired by AbbVie in 2020. The product remained in AbbVie's neuroscience portfolio, but it was substantially smaller than the company's leading immunology, oncology and aesthetics franchises. [2][3]

Public company filings have not consistently reported Viibryd revenue as a standalone line item. The product has generally been grouped with other products or reported within broader therapeutic categories. This limits the precision of public revenue estimates. The most defensible commercial conclusion is that Viibryd was a meaningful mid-sized antidepressant brand before generic entry, but it is not a material growth driver for AbbVie after generic availability.

Market drivers

The main demand drivers are:

  • Continued prevalence of major depressive disorder.
  • Use in adults who do not respond adequately to first-line antidepressants.
  • Physician interest in alternative serotonergic mechanisms.
  • Persistence of branded prescriptions where patients report benefit or tolerability.
  • Use of generic vilazodone when a prescriber or patient seeks the same active ingredient at a lower price.

The main constraints are:

  • Strong competition from inexpensive generic SSRIs and SNRIs.
  • Limited evidence that vilazodone provides broad superiority over established antidepressants.
  • Gastrointestinal adverse effects, including diarrhea and nausea.
  • Administration with food, which can complicate adherence.
  • Generic substitution after FDA approval of ANDAs.
  • Payer pressure on branded antidepressants.

What is the financial trajectory for Viibryd and vilazodone?

Viibryd's financial trajectory follows the standard lifecycle of an oral small-molecule antidepressant:

  1. Launch and brand formation after the 2011 FDA approval.
  2. Revenue expansion during the protected branded period.
  3. Portfolio transfer from Forest Laboratories to Actavis, then Allergan and AbbVie.
  4. Patent litigation and settlement activity as generic applicants approached approval.
  5. Generic entry and rapid price and volume pressure.
  6. Long-term stabilization as a low-priced generic product with limited manufacturer differentiation.

AbbVie does not disclose a current, detailed standalone Viibryd revenue series in its principal public financial reporting. As a result, market participants should not treat older brand-sales estimates as a current valuation proxy. The key financial variable is no longer peak branded revenue. It is the residual share of prescriptions that remain on the branded product after generic substitution.

Revenue exposure by stakeholder

Stakeholder Financial exposure
AbbVie Declining branded revenue, lower promotional return and reduced franchise value after generic entry
Generic manufacturers Low per-unit prices but potential volume across antidepressant prescriptions
Payers Lower net treatment cost through generic substitution
Pharmacies and wholesalers Increased price competition and lower gross margins
Patients Lower acquisition cost, subject to formulary and copayment design
Investors Limited direct exposure because Viibryd is not separately material to AbbVie's consolidated revenue

The generic market can remain commercially relevant even after branded revenue collapses. Vilazodone has a defined indication, established prescribing history and multiple approved tablet strengths. That supports continued generic demand, although the product remains vulnerable to substitution by even cheaper antidepressants.

When does vilazodone lose exclusivity?

Vilazodone lost its practical market exclusivity before the expiration of all listed patents because FDA generic approval and patent settlements can establish launch rights before the last patent expiration date.

The key dates are:

Event Date or period
FDA approval of Viibryd January 2011
New chemical entity exclusivity Expired approximately 2016
Pediatric exclusivity Dependent on FDA-granted pediatric extension; extended the relevant exclusivity period by six months
Core listed patent expiration January 8, 2027, for U.S. Patent No. 7,834,020, subject to statutory adjustments
Generic ANDA approvals Multiple approvals issued by FDA, including approvals reported in 2022
Practical branded exclusivity Effectively ended with commercial generic availability

The distinction between patent expiration and generic market entry is material. A patent may remain listed in the Orange Book while an ANDA applicant receives approval under a Paragraph IV certification, a settlement agreement, a license, or a launch right that begins before the patent expiration date.

What patents protect vilazodone hydrochloride?

The central U.S. patent associated with Viibryd is U.S. Patent No. 7,834,020. The patent covers vilazodone-related compounds and their use in treating central nervous system disorders. Public Orange Book data identify the patent as a principal listed patent for Viibryd, with an expiration date of January 8, 2027. [4]

Patent protection around vilazodone has included several potential layers:

  • Compound and pharmaceutical composition claims.
  • Therapeutic-use claims for depression and related central nervous system disorders.
  • Salt, polymorph or crystalline-form claims.
  • Process or manufacturing claims.
  • Formulation and dosage claims, where applicable.

The practical strength of the estate is weaker than the nominal expiration date suggests. Generic applicants can challenge listed patents, design around narrower formulation or process claims, and negotiate licensed entry. For a conventional immediate-release tablet, the commercial barrier is generally lower than for a complex injectable, controlled-release system or biologic.

How strong is the vilazodone patent estate?

The estate is moderate for a small-molecule antidepressant but does not create a durable post-generic moat.

Patent-estate factor Assessment
Core molecule Historically strong, but late in life cycle
Listed expiration Extends into 2027 for the principal patent
Formulation complexity Limited relative to modified-release products
Manufacturing barrier Manageable for experienced generic manufacturers
Clinical differentiation Moderate, with no broad superiority advantage established
Litigation leverage Meaningful before generic approval, lower after settlements and approvals
Post-entry protection Limited

Which companies challenged Viibryd patents?

Generic applicants commonly challenge branded antidepressant patents through ANDA Paragraph IV certifications. Public litigation and FDA patent records associated with Viibryd included challenges by generic manufacturers seeking approval for vilazodone tablets. Participants in the broader generic competitive field have included companies such as Alembic, Amneal, Lupin, Torrent and Zydus, although the legal posture and commercial launch rights differ by applicant and settlement.

A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. The brand sponsor can sue within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to court and regulatory developments. [5]

The existence of a Paragraph IV case does not establish that the generic will launch immediately. Outcomes include:

  • Patent invalidation.
  • A finding of non-infringement.
  • Settlement with an agreed launch date.
  • License-based early entry.
  • Delayed entry until patent expiration.
  • Commercial launch at risk before final litigation resolution.

What is the Orange Book status of Viibryd?

The FDA Orange Book lists patents and exclusivity information for approved drug products. For Viibryd, the key regulatory issue is the relationship between the listed patent estate and approved generic vilazodone ANDAs.

The Orange Book is not a market-share database. It does not show the volume of generic substitution, the number of prescriptions dispensed or the commercial success of a listed patent. It is a regulatory and patent-transparency tool used by sponsors, ANDA applicants, litigators and investors. [4]

The relevant Orange Book conclusions are:

  • Viibryd had listed U.S. patent protection extending beyond its initial FDA exclusivity period.
  • Generic applicants could rely on ANDA pathways and challenge listed patents.
  • FDA approval of multiple generic products demonstrates that the product's practical exclusivity was no longer intact.
  • The 2027 expiration of the principal listed patent remains relevant to residual patent value, but it does not restore branded market control.

What generic entry risks exist for vilazodone?

Generic entry creates three forms of erosion:

Price erosion

Generic manufacturers compete primarily on acquisition cost, wholesaler terms, pharmacy contracts and payer coverage. Branded Viibryd must offer a clinical or reimbursement advantage to retain volume once an equivalent generic is available.

Volume erosion

Commercial and Medicare plans commonly substitute an approved generic for the branded product unless the prescriber documents medical necessity or the patient has a favorable brand benefit. Volume can fall rapidly after the first generic launch and continue declining as additional manufacturers enter.

Franchise erosion

Generic competition can reduce the value of the brand, sales force allocation, co-pay programs and related commercial infrastructure. A branded product may remain available, but the financial return from promotion is usually reduced.

For generic manufacturers, the principal risks are different. They include price compression, limited market size, competition from numerous ANDA holders, manufacturing disruptions and substitution by other low-cost antidepressants.

How does vilazodone compare with competing antidepressants?

Vilazodone competes against both branded drugs and low-cost generic products.

Drug Class Generic availability Commercial implication
Vilazodone SSRI and 5-HT1A partial agonist Yes Differentiated mechanism, but exposed to generic substitution
Escitalopram SSRI Yes Strong first-line generic competitor
Sertraline SSRI Yes Broad use and very low cost
Fluoxetine SSRI Yes Long clinical history and low cost
Duloxetine SNRI Yes Competes where pain and mood symptoms overlap
Desvenlafaxine SNRI Yes Alternative serotonergic and noradrenergic option
Bupropion Norepinephrine-dopamine reuptake inhibitor Yes Mechanistically differentiated generic alternative
Vortioxetine Multimodal serotonergic antidepressant Brand-led, generic timing varies by jurisdiction Competes on newer mechanism and tolerability positioning
Brexpiprazole adjunctive therapy Atypical antipsychotic Brand and generic dynamics vary Competes in treatment-resistant depression, generally at higher cost

Vilazodone's commercial differentiation is strongest against older SSRIs when physicians value its mechanism or an individual patient has responded well. Its differentiation is weakest when payers apply step therapy or when a prescriber can obtain similar therapeutic objectives with a generic SSRI.

What formulation and manufacturing protections matter?

Vilazodone is a conventional oral tablet rather than a biologic or technically complex delivery system. That reduces manufacturing barriers.

Potential formulation advantages include:

  • Multiple strengths that support dose titration.
  • A defined immediate-release tablet presentation.
  • Established pharmaceutical manufacturing methods.
  • Existing clinical and regulatory data supporting bioequivalence development.

The requirement to administer vilazodone with food is clinically relevant but does not create a strong intellectual-property barrier by itself. Generic manufacturers can generally reproduce the dosage form and demonstrate bioequivalence through FDA requirements rather than repeat the full clinical development program.

Manufacturing risks include active pharmaceutical ingredient sourcing, control of impurities, salt-form consistency, dissolution performance and compliance with current good manufacturing practice. These issues can affect individual generic suppliers, but they do not create a durable market barrier comparable to biologic manufacturing or complex drug-device combination products.

What is the FDA regulatory status of vilazodone?

Viibryd is FDA approved for major depressive disorder in adults. Generic vilazodone hydrochloride tablets have received FDA approval through the ANDA pathway. ANDA approval requires the applicant to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, while relying on the FDA's prior finding of safety and efficacy for the branded product. [1][5]

The regulatory profile is commercially favorable for generic manufacturers because:

  • The reference product has an established safety and efficacy record.
  • The dosage form is an oral tablet.
  • The active ingredient is chemically defined.
  • The product does not require biosimilar development.
  • Generic applications can rely on abbreviated clinical development.

The principal regulatory risks relate to manufacturing compliance, labeling conformity, bioequivalence, supply continuity and post-market adverse-event monitoring.

Is there biosimilar risk for vilazodone?

There is no biosimilar risk in the technical regulatory sense. Vilazodone hydrochloride is a synthetic small molecule, not a biologic. The relevant competitive pathway is the ANDA generic pathway under the Hatch-Waxman framework.

This distinction matters for investment analysis. Generic vilazodone can enter through abbreviated approval without the comparative clinical development burden associated with biosimilars. The result is typically faster competition and more aggressive price erosion once patent and regulatory barriers are cleared.

What licensing deals affect vilazodone?

The product changed ownership through corporate transactions rather than a publicly dominant stand-alone licensing model:

Period Corporate development
2011 Forest Laboratories commercialized Viibryd after FDA approval
2014 Actavis acquired Forest Laboratories
2015 Actavis changed its name to Allergan
2020 AbbVie completed its acquisition of Allergan

These transactions transferred the branded rights and commercial obligations into progressively larger portfolios. Public filings do not identify a current, material third-party licensing structure that changes the core market analysis. Generic manufacturers may obtain rights through patent settlements, but those agreements often contain confidential commercial terms.

What litigation and settlement issues affect vilazodone?

The principal litigation risk has been ANDA patent litigation brought by the brand owner against generic applicants. The business impact depends on the settlement date, permitted launch date, supply terms and whether the agreement includes a license.

Settlement agreements can preserve a portion of brand value by delaying generic entry, but they also establish a ceiling on the remaining exclusivity period. Once multiple generic manufacturers have approval or launch rights, litigation becomes less capable of protecting branded revenue.

The most important legal questions are:

  • Whether the principal patent survives validity and infringement challenges.
  • Whether secondary patents are enforceable and commercially relevant.
  • Whether a generic launch is licensed or at risk.
  • Whether the FDA-approved generic product uses the same strengths and labeling.
  • Whether any settlement terms create a staggered entry sequence.

What generic launch scenarios exist for vilazodone?

Three scenarios define the commercial range:

Scenario Market result
Limited generic participation Slower price erosion, higher residual brand retention and better generic margins
Multiple approved manufacturers Rapid substitution, lower prices and accelerated brand decline
Broad generic commoditization Low-cost product, minimal branded leverage and volume-driven generic economics

The second and third scenarios are more consistent with the commercial profile of an oral antidepressant with multiple ANDA applicants. Brand retention may persist in certain plans or patient segments, but it is unlikely to support historical revenue levels.

Key Takeaways

  • Vilazodone hydrochloride is the active ingredient in Viibryd, an FDA-approved oral antidepressant for adult major depressive disorder.
  • Its dual SSRI and 5-HT1A partial agonist mechanism created product differentiation but did not overcome intense generic SSRI competition.
  • Viibryd's branded revenue trajectory moved from launch growth to mature-franchise decline after generic approvals.
  • U.S. Patent No. 7,834,020 is a principal listed patent with an expiration date of January 8, 2027, subject to statutory adjustments.
  • Multiple generic vilazodone products have been FDA approved, making practical brand exclusivity obsolete before the final listed patent expiration.
  • Vilazodone is subject to generic, not biosimilar, competition.
  • AbbVie does not separately disclose a detailed current Viibryd revenue series, limiting precise standalone valuation.
  • The strongest remaining commercial opportunity is in generic volume, not branded price preservation.
  • The patent estate is moderate, but the conventional tablet format and mature clinical record limit manufacturing and regulatory barriers.
  • Future market value depends on generic concentration, payer substitution, supply reliability and residual brand loyalty.

FAQs

Is vilazodone hydrochloride the same as Viibryd?

Yes. Viibryd is the brand name for vilazodone hydrochloride tablets. Generic vilazodone hydrochloride products contain the same active ingredient and are approved as alternatives to the reference product.

Is vilazodone still under patent in the United States?

The principal listed U.S. patent associated with Viibryd has an expiration date of January 8, 2027. Generic products may nevertheless enter before that date through patent settlements, licenses or successful patent challenges.

Can a generic company launch vilazodone before 2027?

Yes. Patent expiration and commercial launch date are separate issues. FDA approval may follow a Paragraph IV challenge, settlement or license that allows entry before the listed patent expiration.

Does vilazodone have a treatment advantage over sertraline or escitalopram?

Vilazodone has a different pharmacologic profile, but FDA approval does not establish broad superiority over sertraline or escitalopram. Comparative treatment selection depends on response, tolerability, adherence, comorbidities, payer coverage and cost.

What is the investment case for generic vilazodone?

The investment case is volume-based rather than innovation-based. Potential advantages include established demand, multiple tablet strengths and abbreviated FDA approval. Risks include rapid price compression, numerous generic competitors, limited market size and substitution by lower-cost SSRIs.

References

  1. U.S. Food and Drug Administration. (2023). Viibryd prescribing information. FDA.

  2. AbbVie Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

  3. Allergan plc. (2019). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

  5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and ANDA regulatory guidance. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.